Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Locus and Janssen Ink Potential $818 Million Deal

Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.

Read More »

Bristol-Myers to buy Celgene for $74 billion

Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.

Read More »

Boston Scientific Exercises Option to Buy Millipede

Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.

Read More »

Xynomic Pharmaceuticals Picks up Second Cancer Drug From Boehringer Ingelheim in $800 Million Deal

Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II-ready cancer treatment from Germany-based Boehringer Ingelheim.

Read More »

GSK, Pfizer to combine consumer health businesses

GlaxoSmithKline plans to split into two businesses – one for Rx drugs and vaccines, and the other for OTC products – after forming a new joint venture with Pfizer’s consumer health division.

Read More »

Merck Buys Animal Health Company Antelliq

Merck & Co. is paying about $2.4 billion to acquire all outstanding shares of Antelliq Group, and is also assuming the digital technology company’s debt of $1.3 billion.

Read More »

Amgen Terminates $540 Million Deal with Advaxis

Shares of Advaxis plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated their collaboration on an immuno-oncology program.

Read More »

Akorn shares fall after Delaware court rules in favor of Fresenius

The Delaware Supreme Court said in a court filing that Germany’s Fresenius SE properly terminated the company’s merger agreement with Akorn Inc., sending shares of the U.S generic drugmaker down more than 30 percent.

Read More »

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

Akorn Inc. said the company’s chief executive officer would retire following the drugmaker’s inability to salvage a takeover deal with Germany’s Fresenius SE.

Read More »

Despite Opposition, Takeda Shareholders Approve Shire Acquisition

Shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Ireland’s Shire for about $58 billion.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom